First Non-Hormonal Treatment for Hot Flashes Approved by FDA
In an unexpected move, the FDA approved Brisdelle (paroxetine), the first non-hormonal treatment for hot flashes associated with menopause, in spite of a recent panel’s recommendation against the drug.
In an unexpected move, the FDA approved Brisdelle (paroxetine), the first non-hormonal treatment for hot flashes associated with menopause, in spite of a recent panel’s recommendation against the drug.
Brisdelle contains 7.5 mg of paroxetine, a selective serotonin reuptake inhibitor (SSRI) that is used at higher doses to treat depression and anxiety disorders. Two randomized, controlled, double-blind studies in women with moderate to severe hot flashes showed that Brisdelle reduced the frequency and severity of hot flashes.
There was a low occurrence of side effects, most commonly nausea. Because paroxetine is also used to treat depression, it will carry a Boxed Warning about the possibility of the medication increasing suicidality in children and young adults.
Hot flashes affect nearly 75% of women in menopause. Historically, hormone therapy with estrogen has been the only approved pharmacologic treatment, but its side effects and risk profile made it unacceptable for many patients.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Elinzanetant's efficacy for vasomotor symptoms confirmed in phase 3 trial
March 19th 2024Bayer's OASIS 3 trial affirmsed the safety and efficacy of elinzanetant in reducing moderate to severe vasomotor symptoms, bolstering confidence in its potential as a non-hormonal solution for menopause-related issues.
Read More
